Abstract
In a cohort of 483 high-risk patients treated with nirmatrelvir/ritonavir for COVID-19, 2 patients (0.4%) required hospitalization by day 30. Four patients (0.8%) experienced rebound of symptoms, which were generally mild, at a median of 9 days after treatment, and all resolved without additional COVID-19-directed therapy.
Author supplied keywords
Cite
CITATION STYLE
APA
Ranganath, N., O’Horo, J. C., Challener, D. W., Tulledge-Scheitel, S. M., Pike, M. L., O’Brien, M., … Shah, A. (2023). Rebound Phenomenon After Nirmatrelvir/Ritonavir Treatment of Coronavirus Disease 2019 (COVID-19) in High-Risk Persons. Clinical Infectious Diseases, 76(3), E537–E539. https://doi.org/10.1093/cid/ciac481
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free